TY - JOUR
T1 - Genetic and histopathological associations with outcome in pediatric pilocytic astrocytoma
AU - Cler, Samuel J.
AU - Skidmore, Alexander
AU - Yahanda, Alexander T.
AU - Mackey, Kimberly
AU - Rubin, Joshua B.
AU - Cluster, Andrew
AU - Perkins, Stephanie
AU - Gauvain, Karen
AU - King, Allison A.
AU - Limbrick, David D.
AU - McEvoy, Sean
AU - Park, Tae Sung
AU - Smyth, Matthew D.
AU - Mian, Ali Y.
AU - Chicoine, Michael R.
AU - Dahiya, Sonika
AU - Strahle, Jennifer M.
N1 - Funding Information:
HL148305, K12HL137942, UH3HL143192, U01HL143477, UG1HL138669, and U01HL133994. Children’s Discovery Institute grant nos. MC-II-2019-779 and MC-II-2016-524. PCORI CDR-1609-36055; and HRSA grant no. U1EMC27865 (to A.A.K.). I-MiND is supported by Clinical and Translational Science Award (grant no. UL1 TR000448) and the Siteman Comprehensive Cancer Center and NCI Cancer Center Support (grant no. P30 CA091842).
Funding Information:
NIH grant nos. R01CA251112, R01HL129241 B, K24HL148305, K12HL137942, UH3HL143192, U01HL143477, UG1HL138669, and U01HL133994. Children’s Discovery Institute grant nos. MC-II-2019-779 and MC-II-2016-524. PCORI CDR-1609-36055; and HRSA grant no. U1EMC27865 (to A.A.K.). I-MiND is supported by Clinical and Translational Science Award (grant no. UL1 TR000448) and the Siteman Comprehensive Cancer Center and NCI Cancer Center Support (grant no. P30 CA091842).
Funding Information:
NIH grant nos. R01CA251112, R01HL129241 B, K24
Publisher Copyright:
©AANS 2022
PY - 2022/5
Y1 - 2022/5
N2 - OBJECTIVE Pilocytic astrocytomas (PAs) have a generally favorable prognosis; however, progression or recurrence after resection is possible. The prognostic value of histopathological qualifiers (defined below) or BRAF alterations is not well understood. The aim of this study was to identify the prognostic value of genetic and histopathological features of pediatric PAs. METHODS Patients treated for a WHO grade I PA at a single institution were analyzed for histopathological and genetic features and outcomes. “Histopathological qualifier” refers to designations such as “WHO grade I PA with increased proliferative index.” BRAF alterations include gene fusions and point mutations. Patients with neurofibromatosis type 1 were excluded. RESULTS A total of 222 patients were analyzed (51% female, mean age 9.6 years). Tumors were located in the cerebellum/fourth ventricle (51%), optic pathway/hypothalamus (15%), brainstem (12%), and cerebral cortex (11%). BRAF alterations were screened for in 77 patients and identified in 56 (73%). Histopathological qualifiers were present in 27 patients (14%). Resection was performed in 197 patients (89%), 41 (21%) of whom displayed tumor progression or recurrence after resection. Tumor progression or recurrence was not associated with histopathologic qualifiers (p = 0.36) or BRAF alterations (p = 0.77). Ki-67 proliferative indices were not predictive of progression or recurrence (p = 0.94). BRAF alterations, specifically KIAA1549 fusions, were associated with cerebellar/fourth ventricular tumor location (p < 0.0001) and younger patient age (p = 0.03). Patients in whom gross-total resection was achieved had lower rates of progression and recurrence (p < 0.0001). CONCLUSIONS Histopathological features/qualifiers and BRAF alterations were not associated with tumor recurrence/ progression in pediatric PAs. The extent of resection was the only factor analyzed that predicted outcome.
AB - OBJECTIVE Pilocytic astrocytomas (PAs) have a generally favorable prognosis; however, progression or recurrence after resection is possible. The prognostic value of histopathological qualifiers (defined below) or BRAF alterations is not well understood. The aim of this study was to identify the prognostic value of genetic and histopathological features of pediatric PAs. METHODS Patients treated for a WHO grade I PA at a single institution were analyzed for histopathological and genetic features and outcomes. “Histopathological qualifier” refers to designations such as “WHO grade I PA with increased proliferative index.” BRAF alterations include gene fusions and point mutations. Patients with neurofibromatosis type 1 were excluded. RESULTS A total of 222 patients were analyzed (51% female, mean age 9.6 years). Tumors were located in the cerebellum/fourth ventricle (51%), optic pathway/hypothalamus (15%), brainstem (12%), and cerebral cortex (11%). BRAF alterations were screened for in 77 patients and identified in 56 (73%). Histopathological qualifiers were present in 27 patients (14%). Resection was performed in 197 patients (89%), 41 (21%) of whom displayed tumor progression or recurrence after resection. Tumor progression or recurrence was not associated with histopathologic qualifiers (p = 0.36) or BRAF alterations (p = 0.77). Ki-67 proliferative indices were not predictive of progression or recurrence (p = 0.94). BRAF alterations, specifically KIAA1549 fusions, were associated with cerebellar/fourth ventricular tumor location (p < 0.0001) and younger patient age (p = 0.03). Patients in whom gross-total resection was achieved had lower rates of progression and recurrence (p < 0.0001). CONCLUSIONS Histopathological features/qualifiers and BRAF alterations were not associated with tumor recurrence/ progression in pediatric PAs. The extent of resection was the only factor analyzed that predicted outcome.
KW - BRAF
KW - glioma
KW - oncology
KW - pediatrics
KW - pilocytic astrocytoma
UR - http://www.scopus.com/inward/record.url?scp=85130254333&partnerID=8YFLogxK
U2 - 10.3171/2021.9.PEDS21405
DO - 10.3171/2021.9.PEDS21405
M3 - Article
C2 - 35148515
AN - SCOPUS:85130254333
SN - 1933-0707
VL - 29
SP - 504
EP - 512
JO - Journal of Neurosurgery: Pediatrics
JF - Journal of Neurosurgery: Pediatrics
IS - 5
ER -